 | • レポートコード：MRC2012A6602 • 出版社/出版日：GlobalInfoResearch / 2020年12月24日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品、医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、オピオイド誘発性便秘の世界市場を広く調査・分析し、今後の市場展望をまとめております。オピオイド誘発性便秘の種類別市場規模（臭化メチルナルトレキソン、ルビプロストン、ナロキセゴール、その他）、用途別市場規模（病院、薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Takeda Pharmaceuticals、Purdue Pharm、Mallinckrodt、Bayer、Progenics Pharmaceuticals、Sanofi、Daiichi Sankyo、AstraZeneca、Salix (Bausch Health)、Nektar Therapeutics、Prestige、GSK、Shionogi、 ・地域別グローバル市場分析 2015年-2020年 ・オピオイド誘発性便秘の北米市場（アメリカ、カナダ、メキシコ） ・オピオイド誘発性便秘のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・オピオイド誘発性便秘のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・オピオイド誘発性便秘の南米市場（ブラジル、アルゼンチン） ・オピオイド誘発性便秘の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：臭化メチルナルトレキソン、ルビプロストン、ナロキセゴール、その他 ・用途別分析：病院、薬局 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The Opioid-Induced Constipation market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The global Opioid-Induced Constipation market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 4.4%% in the forecast period of 2020 to 2025 and will expected to reach USD 3002.7 million by 2025, from USD 2527.4 million in 2019.
Market segmentation
Opioid-Induced Constipation market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Opioid-Induced Constipation market has been segmented into
Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others
By Application, Opioid-Induced Constipation has been segmented into:
Hospital
Pharmacy
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Opioid-Induced Constipation market presented in the report. This section sheds light on the sales growth of different regional and country-level Opioid-Induced Constipation markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Opioid-Induced Constipation market.
The report offers in-depth assessment of the growth and other aspects of the Opioid-Induced Constipation market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Opioid-Induced Constipation Market Share Analysis
Opioid-Induced Constipation competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Opioid-Induced Constipation sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Opioid-Induced Constipation sales, revenue and market share for each player covered in this report.
The major players covered in Opioid-Induced Constipation are:
Takeda Pharmaceuticals
Purdue Pharm
Mallinckrodt
Bayer
Progenics Pharmaceuticals
Sanofi
Daiichi Sankyo
AstraZeneca
Salix (Bausch Health)
Nektar Therapeutics
Prestige
GSK
Shionogi
Among other players domestic and global, Opioid-Induced Constipation market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Opioid-Induced Constipation product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Opioid-Induced Constipation, with price, sales, revenue and global market share of Opioid-Induced Constipation in 2018 and 2019.
Chapter 3, the Opioid-Induced Constipation competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Opioid-Induced Constipation breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Opioid-Induced Constipation market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Opioid-Induced Constipation sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Opioid-Induced Constipation Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Opioid-Induced Constipation Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Methylnaltrexone Bromide
1.2.3 Lubiprostone
1.2.4 Naloxegol
1.2.5 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Opioid-Induced Constipation Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Overview of Global Opioid-Induced Constipation Market
1.4.1 Global Opioid-Induced Constipation Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Takeda Pharmaceuticals
2.1.1 Takeda Pharmaceuticals Details
2.1.2 Takeda Pharmaceuticals Major Business
2.1.3 Takeda Pharmaceuticals SWOT Analysis
2.1.4 Takeda Pharmaceuticals Product and Services
2.1.5 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Purdue Pharm
2.2.1 Purdue Pharm Details
2.2.2 Purdue Pharm Major Business
2.2.3 Purdue Pharm SWOT Analysis
2.2.4 Purdue Pharm Product and Services
2.2.5 Purdue Pharm Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Mallinckrodt
2.3.1 Mallinckrodt Details
2.3.2 Mallinckrodt Major Business
2.3.3 Mallinckrodt SWOT Analysis
2.3.4 Mallinckrodt Product and Services
2.3.5 Mallinckrodt Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Bayer
2.4.1 Bayer Details
2.4.2 Bayer Major Business
2.4.3 Bayer SWOT Analysis
2.4.4 Bayer Product and Services
2.4.5 Bayer Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Progenics Pharmaceuticals
2.5.1 Progenics Pharmaceuticals Details
2.5.2 Progenics Pharmaceuticals Major Business
2.5.3 Progenics Pharmaceuticals SWOT Analysis
2.5.4 Progenics Pharmaceuticals Product and Services
2.5.5 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Sanofi
2.6.1 Sanofi Details
2.6.2 Sanofi Major Business
2.6.3 Sanofi Product and Services
2.6.4 Sanofi Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Daiichi Sankyo
2.7.1 Daiichi Sankyo Details
2.7.2 Daiichi Sankyo Major Business
2.7.3 Daiichi Sankyo Product and Services
2.7.4 Daiichi Sankyo Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 AstraZeneca
2.8.1 AstraZeneca Details
2.8.2 AstraZeneca Major Business
2.8.3 AstraZeneca Product and Services
2.8.4 AstraZeneca Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 Salix (Bausch Health)
2.9.1 Salix (Bausch Health) Details
2.9.2 Salix (Bausch Health) Major Business
2.9.3 Salix (Bausch Health) Product and Services
2.9.4 Salix (Bausch Health) Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.10 Nektar Therapeutics
2.10.1 Nektar Therapeutics Details
2.10.2 Nektar Therapeutics Major Business
2.10.3 Nektar Therapeutics Product and Services
2.10.4 Nektar Therapeutics Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.11 Prestige
2.11.1 Prestige Details
2.11.2 Prestige Major Business
2.11.3 Prestige Product and Services
2.11.4 Prestige Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.12 GSK
2.12.1 GSK Details
2.12.2 GSK Major Business
2.12.3 GSK Product and Services
2.12.4 GSK Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.13 Shionogi
2.13.1 Shionogi Details
2.13.2 Shionogi Major Business
2.13.3 Shionogi Product and Services
2.13.4 Shionogi Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Opioid-Induced Constipation Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Opioid-Induced Constipation Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Opioid-Induced Constipation Manufacturer Market Share in 2019
3.3.2 Top 6 Opioid-Induced Constipation Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Opioid-Induced Constipation Sales, Revenue and Market Share by Regions
4.1.1 Global Opioid-Induced Constipation Sales and Market Share by Regions (2015-2020)
4.1.2 Global Opioid-Induced Constipation Revenue and Market Share by Regions (2015-2020)
4.2 North America Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
4.3 Europe Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
4.5 South America Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Opioid-Induced Constipation Sales, Revenue and Market Share by Country
5.1.1 North America Opioid-Induced Constipation Sales and Market Share by Country (2015-2020)
5.1.2 North America Opioid-Induced Constipation Revenue and Market Share by Country (2015-2020)
5.2 United States Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
5.3 Canada Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
5.4 Mexico Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Opioid-Induced Constipation Sales, Revenue and Market Share by Country
6.1.1 Europe Opioid-Induced Constipation Sales and Market Share by Country (2015-2020)
6.1.2 Europe Opioid-Induced Constipation Revenue and Market Share by Country (2015-2020)
6.2 Germany Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
6.3 UK Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
6.4 France Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
6.5 Russia Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
6.6 Italy Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Opioid-Induced Constipation Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Opioid-Induced Constipation Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Opioid-Induced Constipation Revenue and Market Share by Regions (2015-2020)
7.2 China Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
7.3 Japan Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
7.4 Korea Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
7.5 India Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
7.7 Australia Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Opioid-Induced Constipation Sales, Revenue and Market Share by Country
8.1.1 South America Opioid-Induced Constipation Sales and Market Share by Country (2015-2020)
8.1.2 South America Opioid-Induced Constipation Revenue and Market Share by Country (2015-2020)
8.2 Brazil Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
8.3 Argentina Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Opioid-Induced Constipation Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Opioid-Induced Constipation Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Opioid-Induced Constipation Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
9.3 Turkey Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
9.4 Egypt Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
9.5 South Africa Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Opioid-Induced Constipation Sales and Market Share by Type (2015-2020)
10.2 Global Opioid-Induced Constipation Revenue and Market Share by Type (2015-2020)
10.3 Global Opioid-Induced Constipation Price by Type (2015-2020)
11 Global Opioid-Induced Constipation Market Segment by Application
11.1 Global Opioid-Induced Constipation Sales Market Share by Application (2015-2020)
11.2 Global Opioid-Induced Constipation Revenue Market Share by Application (2015-2020)
11.3 Global Opioid-Induced Constipation Price by Application (2015-2020)
12 Market Forecast
12.1 Global Opioid-Induced Constipation Sales, Revenue and Growth Rate (2021-2025)
12.2 Opioid-Induced Constipation Market Forecast by Regions (2021-2025)
12.2.1 North America Opioid-Induced Constipation Market Forecast (2021-2025)
12.2.2 Europe Opioid-Induced Constipation Market Forecast (2021-2025)
12.2.3 Asia-Pacific Opioid-Induced Constipation Market Forecast (2021-2025)
12.2.4 South America Opioid-Induced Constipation Market Forecast (2021-2025)
12.2.5 Middle East & Africa Opioid-Induced Constipation Market Forecast (2021-2025)
12.3 Opioid-Induced Constipation Market Forecast by Type (2021-2025)
12.3.1 Global Opioid-Induced Constipation Sales Forecast by Type (2021-2025)
12.3.2 Global Opioid-Induced Constipation Market Share Forecast by Type (2021-2025)
12.4 Opioid-Induced Constipation Market Forecast by Application (2021-2025)
12.4.1 Global Opioid-Induced Constipation Sales Forecast by Application (2021-2025)
12.4.2 Global Opioid-Induced Constipation Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Opioid-Induced Constipation Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Opioid-Induced Constipation by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Opioid-Induced Constipation Market Size and Growth Estimation in Various Scenarios in 2020
Table 4. Global Opioid-Induced Constipation Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 5. Market Opportunities in Next Few Years
Table 6. Market Risks Analysis
Table 7. Market Drivers
Table 8. Takeda Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 9. Takeda Pharmaceuticals Opioid-Induced Constipation Major Business
Table 10. Takeda Pharmaceuticals Opioid-Induced Constipation Total Revenue (USD Million) (2018-2019)
Table 11. Takeda Pharmaceuticals SWOT Analysis
Table 12. Takeda Pharmaceuticals Opioid-Induced Constipation Product and Services
Table 13. Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 14. Purdue Pharm Basic Information, Manufacturing Base and Competitors
Table 15. Purdue Pharm Opioid-Induced Constipation Major Business
Table 16. Purdue Pharm Opioid-Induced Constipation Total Revenue (USD Million) (2018-2019)
Table 17. Purdue Pharm SWOT Analysis
Table 18. Purdue Pharm Opioid-Induced Constipation Product and Services
Table 19. Purdue Pharm Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 20. Mallinckrodt Basic Information, Manufacturing Base and Competitors
Table 21. Mallinckrodt Opioid-Induced Constipation Major Business
Table 22. Mallinckrodt Opioid-Induced Constipation Total Revenue (USD Million) (2018-2019)
Table 23. Mallinckrodt SWOT Analysis
Table 24. Mallinckrodt Opioid-Induced Constipation Product and Services
Table 25. Mallinckrodt Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 26. Bayer Basic Information, Manufacturing Base and Competitors
Table 27. Bayer Opioid-Induced Constipation Major Business
Table 28. Bayer Opioid-Induced Constipation Total Revenue (USD Million) (2018-2019)
Table 29. Bayer SWOT Analysis
Table 30. Bayer Opioid-Induced Constipation Product and Services
Table 31. Bayer Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 32. Progenics Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 33. Progenics Pharmaceuticals Opioid-Induced Constipation Major Business
Table 34. Progenics Pharmaceuticals Opioid-Induced Constipation Total Revenue (USD Million) (2018-2019)
Table 35. Progenics Pharmaceuticals SWOT Analysis
Table 36. Progenics Pharmaceuticals Opioid-Induced Constipation Product and Services
Table 37. Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 38. Sanofi Basic Information, Manufacturing Base and Competitors
Table 39. Sanofi Opioid-Induced Constipation Major Business
Table 40. Sanofi Opioid-Induced Constipation Total Revenue (USD Million) (2018-2019)
Table 41. Sanofi SWOT Analysis
Table 42. Sanofi Opioid-Induced Constipation Product and Services
Table 43. Sanofi Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 44. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
Table 45. Daiichi Sankyo Opioid-Induced Constipation Major Business
Table 46. Daiichi Sankyo Opioid-Induced Constipation Total Revenue (USD Million) (2018-2019)
Table 47. Daiichi Sankyo SWOT Analysis
Table 48. Daiichi Sankyo Opioid-Induced Constipation Product and Services
Table 49. Daiichi Sankyo Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 50. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 51. AstraZeneca Opioid-Induced Constipation Major Business
Table 52. AstraZeneca Opioid-Induced Constipation Total Revenue (USD Million) (2018-2019)
Table 53. AstraZeneca SWOT Analysis
Table 54. AstraZeneca Opioid-Induced Constipation Product and Services
Table 55. AstraZeneca Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 56. Salix (Bausch Health) Basic Information, Manufacturing Base and Competitors
Table 57. Salix (Bausch Health) Opioid-Induced Constipation Major Business
Table 58. Salix (Bausch Health) Opioid-Induced Constipation Total Revenue (USD Million) (2018-2019)
Table 59. Salix (Bausch Health) SWOT Analysis
Table 60. Salix (Bausch Health) Opioid-Induced Constipation Product and Services
Table 61. Salix (Bausch Health) Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 62. Nektar Therapeutics Basic Information, Manufacturing Base and Competitors
Table 63. Nektar Therapeutics Opioid-Induced Constipation Major Business
Table 64. Nektar Therapeutics Opioid-Induced Constipation Total Revenue (USD Million) (2018-2019)
Table 65. Nektar Therapeutics SWOT Analysis
Table 66. Nektar Therapeutics Opioid-Induced Constipation Product and Services
Table 67. Nektar Therapeutics Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 68. Prestige Basic Information, Manufacturing Base and Competitors
Table 69. Prestige Opioid-Induced Constipation Major Business
Table 70. Prestige Opioid-Induced Constipation Total Revenue (USD Million) (2018-2019)
Table 71. Prestige SWOT Analysis
Table 72. Prestige Opioid-Induced Constipation Product and Services
Table 73. Prestige Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 74. GSK Basic Information, Manufacturing Base and Competitors
Table 75. GSK Opioid-Induced Constipation Major Business
Table 76. GSK Opioid-Induced Constipation Total Revenue (USD Million) (2018-2019)
Table 77. GSK SWOT Analysis
Table 78. GSK Opioid-Induced Constipation Product and Services
Table 79. GSK Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 80. Shionogi Basic Information, Manufacturing Base and Competitors
Table 81. Shionogi Opioid-Induced Constipation Major Business
Table 82. Shionogi Opioid-Induced Constipation Total Revenue (USD Million) (2018-2019)
Table 83. Shionogi SWOT Analysis
Table 84. Shionogi Opioid-Induced Constipation Product and Services
Table 85. Shionogi Opioid-Induced Constipation Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 86. Global Opioid-Induced Constipation Sales by Manufacturer (2018-2019) (K Units)
Table 87. Global Opioid-Induced Constipation Revenue by Manufacturer (2018-2019) (USD Million)
Table 88. Global Opioid-Induced Constipation Sales by Regions (2015-2020) (K Units)
Table 89. Global Opioid-Induced Constipation Sales Market Share by Regions (2015-2020)
Table 90. Global Opioid-Induced Constipation Revenue by Regions (2015-2020) (USD Million)
Table 91. North America Opioid-Induced Constipation Sales by Countries (2015-2020) (K Units)
Table 92. North America Opioid-Induced Constipation Sales Market Share by Countries (2015-2020)
Table 93. North America Opioid-Induced Constipation Revenue by Countries (2015-2020) (USD Million)
Table 94. North America Opioid-Induced Constipation Revenue Market Share by Countries (2015-2020)
Table 95. Europe Opioid-Induced Constipation Sales by Countries (2015-2020) (K Units)
Table 96. Europe Opioid-Induced Constipation Sales Market Share by Countries (2015-2020)
Table 97. Europe Opioid-Induced Constipation Revenue by Countries (2015-2020) (USD Million)
Table 98. Asia-Pacific Opioid-Induced Constipation Sales by Regions (2015-2020) (K Units)
Table 99. Asia-Pacific Opioid-Induced Constipation Sales Market Share by Regions (2015-2020)
Table 100. Asia-Pacific Opioid-Induced Constipation Revenue by Regions (2015-2020) (USD Million)
Table 101. South America Opioid-Induced Constipation Sales by Countries (2015-2020) (K Units)
Table 102. South America Opioid-Induced Constipation Sales Market Share by Countries (2015-2020)
Table 103. South America Opioid-Induced Constipation Revenue by Countries (2015-2020) (USD Million)
Table 104. South America Opioid-Induced Constipation Revenue Market Share by Countries (2015-2020)
Table 105. Middle East & Africa Opioid-Induced Constipation Sales by Countries (2015-2020) (K Units)
Table 106. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Countries (2015-2020)
Table 107. Middle East & Africa Opioid-Induced Constipation Revenue by Countries (2015-2020) (USD Million)
Table 108. Middle East & Africa Opioid-Induced Constipation Revenue Market Share by Countries (2015-2020)
Table 109. Global Opioid-Induced Constipation Sales by Type (2015-2020) (K Units)
Table 110. Global Opioid-Induced Constipation Sales Share by Type (2015-2020)
Table 111. Global Opioid-Induced Constipation Revenue by Type (2015-2020) (USD Million)
Table 112. Global Opioid-Induced Constipation Revenue Share by Type (2015-2020)
Table 113. Global Opioid-Induced Constipation Sales by Application (2015-2020) (K Units)
Table 114. Global Opioid-Induced Constipation Sales Share by Application (2015-2020)
Table 115. Global Opioid-Induced Constipation Sales Forecast by Regions (2021-2025) (K Units)
Table 116. Global Opioid-Induced Constipation Market Share Forecast by Regions (2021-2025)
Table 117. Global Opioid-Induced Constipation Sales Forecast by Type (2021-2025) (K Units)
Table 118. Global Opioid-Induced Constipation Market Share Forecast by Type (2021-2025)
Table 119. Global Opioid-Induced Constipation Sales Forecast by Application (2021-2025)
Table 120. Global Opioid-Induced Constipation Market Share Forecast by Application (2021-2025)
Table 121. Direct Channel Pros & Cons
Table 122. Indirect Channel Pros & Cons
Table 123. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Opioid-Induced Constipation Picture
Figure 2. Global Sales Market Share of Opioid-Induced Constipation by Type in 2019
Figure 3. Methylnaltrexone Bromide Picture
Figure 4. Lubiprostone Picture
Figure 5. Naloxegol Picture
Figure 6. Others Picture
Figure 7. Opioid-Induced Constipation Sales Market Share by Application in 2019
Figure 8. Hospital Picture
Figure 9. Pharmacy Picture
Figure 10. Global Opioid-Induced Constipation Market Status and Outlook (2015-2025) (USD Million)
Figure 11. United States Opioid-Induced Constipation Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Canada Opioid-Induced Constipation Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Mexico Opioid-Induced Constipation Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Germany Opioid-Induced Constipation Revenue (Value) and Growth Rate (2015-2025)
Figure 15. France Opioid-Induced Constipation Revenue (Value) and Growth Rate (2015-2025)
Figure 16. UK Opioid-Induced Constipation Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Russia Opioid-Induced Constipation Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Italy Opioid-Induced Constipation Revenue (Value) and Growth Rate (2015-2025)
Figure 19. China Opioid-Induced Constipation Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Japan Opioid-Induced Constipation Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Korea Opioid-Induced Constipation Revenue (Value) and Growth Rate (2015-2025)
Figure 22. India Opioid-Induced Constipation Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Southeast Asia Opioid-Induced Constipation Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Australia Opioid-Induced Constipation Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 25. Brazil Opioid-Induced Constipation Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Egypt Opioid-Induced Constipation Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Saudi Arabia Opioid-Induced Constipation Revenue (Value) and Growth Rate (2015-2025)
Figure 28. South Africa Opioid-Induced Constipation Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Turkey Opioid-Induced Constipation Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Global Opioid-Induced Constipation Sales Market Share by Manufacturer in 2019
Figure 31. Global Opioid-Induced Constipation Revenue Market Share by Manufacturer in 2019
Figure 32. Top 3 Opioid-Induced Constipation Manufacturer (Revenue) Market Share in 2019
Figure 33. Top 6 Opioid-Induced Constipation Manufacturer (Revenue) Market Share in 2019
Figure 34. Key Manufacturer Market Share Trend
Figure 35. Global Opioid-Induced Constipation Sales and Growth Rate (2015-2020) (K Units)
Figure 36. Global Opioid-Induced Constipation Revenue and Growth Rate (2015-2020) (USD Million)
Figure 37. Global Opioid-Induced Constipation Revenue Market Share by Regions (2015-2020)
Figure 38. Global Opioid-Induced Constipation Revenue Market Share by Regions in 2018
Figure 39. North America Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
Figure 40. Europe Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
Figure 42. South America Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
Figure 43. Middle East & Africa Opioid-Induced Constipation Sales and Growth Rate (2015-2020)
Figure 44. North America Opioid-Induced Constipation Revenue and Growth Rate (2015-2020) (USD Million)
Figure 45. North America Opioid-Induced Constipation Sales Market Share by Countries (2015-2020)
Figure 46. North America Opioid-Induced Constipation Sales Market Share by Countries in 2018
Figure 47. North America Opioid-Induced Constipation Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 48. North America Opioid-Induced Constipation Revenue Market Share by Countries in 2018
Figure 49. United States Opioid-Induced Constipation Sales and Growth Rate (2015-2020) (K Units)
Figure 50. Canada Opioid-Induced Constipation Sales and Growth Rate (2015-2020) (K Units)
Figure 51. Mexico Opioid-Induced Constipation Sales and Growth Rate (2015-2020) (K Units)
Figure 52. Europe Opioid-Induced Constipation Revenue and Growth Rate (2015-2020) (USD Million)
Figure 53. Europe Opioid-Induced Constipation Revenue Market Share by Countries (2015-2020)
Figure 54. Europe Opioid-Induced Constipation Revenue Market Share by Countries in 2019
Figure 55. Germany Opioid-Induced Constipation Sales and Growth Rate (2015-2020) (K Units)
Figure 56. UK Opioid-Induced Constipation Sales and Growth Rate (2015-2020) (K Units)
Figure 57. France Opioid-Induced Constipation Sales and Growth Rate (2015-2020) (K Units)
Figure 58. Russia Opioid-Induced Constipation Sales and Growth Rate (2015-2020) (K Units)
Figure 59. Italy Opioid-Induced Constipation Sales and Growth Rate (2015-2020) (K Units)
Figure 60. Asia-Pacific Opioid-Induced Constipation Revenue and Growth Rate (2015-2020) (USD Million)
Figure 61. Asia-Pacific Opioid-Induced Constipation Sales Market Share by Regions 2019
Figure 62. Asia-Pacific Opioid-Induced Constipation Revenue Market Share by Regions 2019
Figure 63. China Opioid-Induced Constipation Sales and Growth Rate (2015-2020) (K Units)
Figure 64. Japan Opioid-Induced Constipation Sales and Growth Rate (2015-2020) (K Units)
Figure 65. Korea Opioid-Induced Constipation Sales and Growth Rate (2015-2020) (K Units)
Figure 66. India Opioid-Induced Constipation Sales and Growth Rate (2015-2020) (K Units)
Figure 67. Southeast Asia Opioid-Induced Constipation Sales and Growth Rate (2015-2020) (K Units)
Figure 68. South America Opioid-Induced Constipation Revenue and Growth Rate (2015-2020) (USD Million)
Figure 69. South America Opioid-Induced Constipation Sales Market Share by Countries in 2019
Figure 70. South America Opioid-Induced Constipation Revenue Market Share by Countries in 2019
Figure 71. Brazil Opioid-Induced Constipation Sales and Growth Rate (2015-2020) (K Units)
Figure 72. Argentina Opioid-Induced Constipation Sales and Growth Rate (2015-2020) (K Units)
Figure 73. Middle East and Africa Opioid-Induced Constipation Revenue and Growth Rate (2015-2020) (USD Million)
Figure 74. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Countries in 2019
Figure 75. Middle East and Africa Opioid-Induced Constipation Revenue Market Share by Countries (2015-2020)
Figure 76. Middle East and Africa Opioid-Induced Constipation Revenue Market Share by Countries in 2019
Figure 77. Saudi Arabia Opioid-Induced Constipation Sales and Growth Rate (2015-2020) (K Units)
Figure 78. Egypt Opioid-Induced Constipation Sales and Growth Rate (2015-2020) (K Units)
Figure 79. Turkey Opioid-Induced Constipation Sales and Growth Rate (2015-2020) (K Units)
Figure 80. South Africa Opioid-Induced Constipation Sales and Growth Rate (2015-2020) (K Units)
Figure 81. Global Opioid-Induced Constipation Sales and Growth Rate (2021-2025) (K Units)
Figure 82. Global Opioid-Induced Constipation Revenue and Growth Rate (2021-2025) (USD Million)
Figure 83. North America Sales Opioid-Induced Constipation Market Forecast (2021-2025) (K Units)
Figure 84. Europe Sales Opioid-Induced Constipation Market Forecast (2021-2025) (K Units)
Figure 85. Asia-Pacific Sales Opioid-Induced Constipation Market Forecast (2021-2025) (K Units)
Figure 86. South America Sales Opioid-Induced Constipation Market Forecast (2021-2025) (K Units)
Figure 87. Middle East & Africa Sales Opioid-Induced Constipation Market Forecast (2021-2025) (K Units)
Figure 88. Sales Channel: Direct Channel vs Indirect Channel
オピオイド誘発性便秘治療の世界市場（～2026年） There are multiple drugs in the pipeline for opioid induced constipation treatment. Upon approval, these drugs will face little competition in this market which is largely untapped. There have not been many stable choices in the pharmaceutical industry for opioid induced constipation treatment over …- オピオイド誘発性便秘（OIC）治療の世界市場（～2026年） Market Analysis and Insights: Global Opioid-Induced Constipation (OIC) Treatment Market The global Opioid-Induced Constipation (OIC) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Opioid-Induced Constipation…
- オピオイド誘発性便秘治療薬の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Opioid Induced Constipation Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Opioid Indu…
- オピオイド誘発性便秘（OIC）治療薬の世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The global Opioid Induced Constipation (OIC) Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Opioi…
- オピオイド誘発性便秘（OIC）治療薬の世界市場（～2026年） Opioid-induced constipation (OIC) is a common adverse effect experienced by many patients on opioid therapy for chronic pain. OTC medications include stimulant laxatives, stool softeners, and enemas. Market Analysis and Insights: Global Opioid Induced Constipation (OIC) Drug Market The global Opioid…